Amjodaronum en es it fr

Amjodaronum Brand names, Amjodaronum Analogs

Amjodaronum Brand Names Mixture

  • No information avaliable

Amjodaronum Chemical_Formula


Amjodaronum RX_link

Amjodaronum fda sheet

Amjodaronum FDA

Amjodaronum msds (material safety sheet)

Amjodaronum MSDS

Amjodaronum Synthesis Reference

No information avaliable

Amjodaronum Molecular Weight

645.312 g/mol

Amjodaronum Melting Point

No information avaliable

Amjodaronum H2O Solubility


Amjodaronum State


Amjodaronum LogP


Amjodaronum Dosage Forms

Liquid; Solution; Tablet (200 mg and 400 mg)

Amjodaronum Indication

Intravenously, for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. Orally, for the treatment of life-threatening recurrent ventricular arrhythmias such as recurrent ventricular fibrillation and recurrent hemodynamically unstable ventricular tachycardia.

Amjodaronum Pharmacology

Amiodarone belongs to a class of drugs called Vaughan-Williams Class III antiarrhythmic agents. It is used in the treatment of a wide range of cardiac tachyarhthmias, including both ventricular and supraventricular (atrial) arrhythmias. After intravenous administration in man, amiodarone relaxes vascular smooth muscle, reduces peripheral vascular resistance (afterload), and slightly increases cardiac index. Amiodarone prolongs phase 3 of the cardiac action potential. It has numerous other effects however, including actions that are similar to those of antiarrhythmic classes Ia, II, and IV. Amiodarone shows beta blocker-like and calcium channel blocker-like actions on the SA and AV nodes, increases the refractory period via sodium- and potassium-channel effects, and slows intra-cardiac conduction of the cardiac action potential, via sodium-channel effects.

Amjodaronum Absorption

Slow and variable (about 20 to 55% of an oral dose is absorbed).

Amjodaronum side effects and Toxicity

Intravenous, mouse: LD50 = 178 mg/kg. Some side effects have a significant mortality rate: specifically, hepatitis, exacerbation of asthma and congestive failure, and pneumonitis.

Amjodaronum Patient Information

No information avaliable

Amjodaronum Organisms Affected

Humans and other mammals